Loading
ADRA2C (Alpha-2C adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes literature 0.90, genetic association 0.40, clinical 0.81).
In plain words · ADRA2C (Alpha-2C adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
ADRA2C (Alpha-2C adrenergic receptor) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression.
No product in this corpus aims at ADRA2C yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ADRA2C: RNA tissue enhanced (blood vessel 102 nTPM, cervix 61 nTPM, endometrium 1 54 nTPM); no normal tissue stained high; highest cancer staining cervical cancer (1 of 12 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ADRA2C tissue; Open Targets ENSG00000184160 associations
First described 1988. Earliest sequence paper UniProt cites for the protein: Regan J.W. et al, Proc. Natl. Acad. Sci. U.S.A, 1988, "Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype". Source.
Sources: HGNC HGNC:283 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P18825 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000184160 (association with cancer (MONDO_0004992) 0.57; (GraphQL API, CC0))
Alpha-2 adrenergic receptors are G protein-coupled receptors for catecholamines that activate the G(i/o) protein pathway, thereby promoting adenylyl cyclase inhibition, ERK1/2 stimulation, and voltage-gated calcium channels suppression. Control a variety of physiological processes, such as regulation of blood pressure, lipolysis and insulin release. ADRA2A and ADRA2C mediates the presynaptic feedback inhibition of neurotransmitter release from noradrenergic nerve terminals in sympathetic and central nervous systems. ADRA2A inhibits transmitter release at high stimulation frequencies, whereas ADRA2C modulates neurotransmission at lower levels of nerve activity. The rank order of potency for physiological agonists of ADRA2C is epinephrine > norepinephrine > dopamine. Location: Cell membrane (UniProt). Locus 4p16.3 (HGNC).
RNA: tissue enhanced (blood vessel 102 nTPM, cervix 61 nTPM, endometrium 1 54 nTPM), detected in many normal tissues.
No normal tissue stained high.
RNA cancer enhanced: Ovary Serous Cystadenocarcinoma 31 pTPM.
Medium only: liver cancer.
HPA ADRA2C tissue · HPA ADRA2C pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ADRA2C" OR ABSTRACT:"ADRA2C" OR TITLE:"adrenoceptor alpha 2C" OR ABSTRACT:"adrenoceptor alpha 2C" OR TITLE:"Alpha-2C adrenergic receptor" OR ABSTRACT:"Alpha-2C adrenergic receptor" OR TITLE:"ADRARL2" OR ABSTRACT:"ADRARL2" OR TITLE:"ADRA2L2" OR ABSTRACT:"ADRA2L2" OR TITLE:"ADRA2RL2" OR ABSTRACT:"ADRA2RL2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ADRA2C, not a curated reading list.